Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.

BMC Cancer · 2011 · PMC3161035 · PMID 21791091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Discussion The present subgroup analysis of the CERTIFY trial resulted in the following findings: 1) Thromboembolic events were reduced from 6.03 to 4.50% with the use of certoparin in comparison with UFH, although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.